The Native Antigen Company, a UK-based supplier of reagents enabling research into vaccines and diagnostics for emerging and endemic infectious diseases, has introduced its novel coronavirus antigens derived from the Corvid-19 strain.
According to the Oxfordshire company, these recombinant proteins offer scientists high-quality reagents to support ongoing infectious disease research, and the development of diagnostics and vaccines.
The antigens have been derived specifically from the newly identified Corvid-19 using The Native Antigen Company’s proprietary mammalian, VirtuE expression system. This system is able to introduce proper protein folding and post-translational modifications to recombinant proteins, which are essential for full biological and antigenic activity.
“The Native Antigen Company’s Coronavirus antigens could aid the development of accurate serological assays to identify asymptomatic individuals who have been infected by the virus, and help to assess the true level of infection in any population,” said to Professor Richard Tedder from the Department of Infectious Disease at Imperial College London.
“The availability of these antigens also supports researchers’ efforts to rapidly develop a vaccine against 2019-nCoV by providing vital reagents to measure vaccine responses.”